Hikma Pharmaceuticals USA INC. recalls
5 notices naming Hikma Pharmaceuticals USA INC. as the recalling firm, since August 6, 2025. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Hikma Pharmaceuticals USA INC.: Ciprofloxacin Tablets and 1 more
Hazard (FDA): CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
FDAMedicines
Hikma Pharmaceuticals USA INC.: Abirtega
Hazard (FDA): Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.
FDAMedicines
Hikma Pharmaceuticals USA INC.: Ramipril Capsules USP
Hazard (FDA): Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
FDAMedicines
Hikma Pharmaceuticals USA INC: Alendronate Sodium Oral Solution
Hazard (FDA): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.
FDAMedicines
Hikma Pharmaceuticals USA Inc.: Lorazepam Injection
Hazard (FDA): Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds
FDAMedicines